These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33615886)

  • 1. The Vital Role of Proteomics in Characterizing Novel Protein Degraders.
    Zhang AX; Cassidy K; Dahl G; Moreau K; Pachl F; Zuhl AM
    SLAS Discov; 2021 Apr; 26(4):518-523. PubMed ID: 33615886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts.
    Chernobrovkin AL; Cázares-Körner C; Friman T; Caballero IM; Amadio D; Martinez Molina D
    SLAS Discov; 2021 Apr; 26(4):534-546. PubMed ID: 33445986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics.
    Simard JR; Lee L; Vieux E; Improgo R; Tieu T; Phillips AJ; Fisher SL; Pollock RM; Park E
    SLAS Discov; 2021 Apr; 26(4):503-517. PubMed ID: 33430712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target Validation Using PROTACs: Applying the Four Pillars Framework.
    Nowak RP; Jones LH
    SLAS Discov; 2021 Apr; 26(4):474-483. PubMed ID: 33334221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches.
    Scholes NS; Mayor-Ruiz C; Winter GE
    Cell Chem Biol; 2021 Jul; 28(7):1048-1060. PubMed ID: 33811812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted protein degradation and the enzymology of degraders.
    Fisher SL; Phillips AJ
    Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on the development of first-in-class protein degraders.
    Rambacher KM; Calabrese MF; Yamaguchi M
    Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of high throughput screening outputs for small molecule degrader discovery.
    Bell LE; Bardelle C; Packer MJ; Kastl J; Holdgate GA; Davies G
    SLAS Discov; 2024 Jul; 29(5):100162. PubMed ID: 38797285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bifunctional Molecules beyond PROTACs.
    Conway SJ
    J Med Chem; 2020 Mar; 63(6):2802-2806. PubMed ID: 32157887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs.
    Winter GE
    ACS Chem Biol; 2024 Oct; 19(10):2089-2102. PubMed ID: 39264973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROTACs: New method to degrade transcription regulating proteins.
    Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
    Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.